Victor Byrd, MD
Rheumatology · Nashville, TNNPI 1952392797
Payments from drug & device makers
Across 1,561 payments — averaging $158.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$80K
- Lilly USA, LLC$44K
- Novartis$42K
- Amgen$34K
- Bristol Myers Squibb$25K
- E.r. Squibb & Sons, L.L.C.$9K
- plus $13K from 28 others
What the payments were for
- Consulting fees$22,9249%
- Speaking & faculty fees$182,87274%
- Travel & lodging$14,6096%
- Food & beverage$26,28711%
- Education$2320%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 378 | $80,040 |
| Lilly USA, LLC | 133 | $44,167 |
| Novartis | 178 | $42,486 |
| Amgen(2 entities) | 312 | $33,962 |
| Bristol Myers Squibb | 47 | $24,539 |
| E.r. Squibb & Sons, L.L.C. | 38 | $9,070 |
| Johnson & Johnson(2 entities) | 71 | $3,658 |
| UCB, Inc. | 132 | $2,280 |
| Fresenius Kabi USA, LLC | 20 | $1,596 |
| AstraZeneca(2 entities) | 48 | $1,106 |
| Pfizer | 59 | $1,006 |
| GSK | 22 | $446 |
| ANI Pharmaceuticals, Inc. | 15 | $390 |
| Boehringer Ingelheim | 12 | $259 |
| Aurinia Pharma U.S., Inc. | 13 | $228 |
| Mallinckrodt Hospital Products Inc. | 8 | $217 |
| Sanofi | 8 | $211 |
| Sobi, Inc | 11 | $203 |
| Radius Health, Inc. | 8 | $169 |
| Organon | 8 | $158 |
| Genentech USA, Inc. | 8 | $148 |
| Pacira Therapeutics, Inc. | 8 | $129 |
| Alnylam Pharmaceuticals Inc. | 4 | $70 |
| Teva Pharmaceuticals USA, Inc. | 4 | $68 |
| Kiniksa Pharmaceuticals, Ltd. | 3 | $58 |
| Celltrion USA Inc. | 2 | $48 |
| Actelion Pharmaceuticals US, Inc. | 2 | $48 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $38 |
| Tersera Therapeutics LLC | 1 | $38 |
| Sandoz | 2 | $37 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Mylan Institutional Inc. | 1 | $14 |
| Hikma Pharmaceuticals USA | 1 | $13 |
| Sanofi-aventis U.S. LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$246,924 in reported general payments places this provider in the 90th percentile of 127 rheumatology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 157 | $1,286,574 |
| Humira(Cf) PenAdalimumab | 94 | $924,303 |
| EnbrelEtanercept | 52 | $486,213 |
| RinvoqUpadacitinib | 39 | $243,995 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 27 | $204,136 |
| OrenciaAbatacept | 23 | $158,579 |
| Humira(Cf)Adalimumab | 15 | $149,773 |
| Xeljanz XrTofacitinib Citrate | 21 | $119,030 |
| Cosentyx Sensoready PenSecukinumab | 14 | $100,298 |
| OtezlaApremilast | 16 | $94,458 |
| BenlystaBelimumab | 15 | $77,572 |
| HumiraAdalimumab | 11 | $76,538 |
| Hydroxychloroquine Sulfate | 1,358 | $57,630 |
| OlumiantBaricitinib | 13 | $34,549 |
| OxycontinOxycodone Hcl | 26 | $30,438 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenEnbrel, Otezla | $33,962 | $580,67168 claims |
| AbbVieRinvoq, Humira(Cf), Humira | $80,040 | $470,30665 claims |
| E.r. Squibb & Sons, L.L.C.Orencia | $9,070 | $158,57923 claims |
| GSKBenlysta | $446 | $77,57215 claims |
| Lilly USA, LLCOlumiant | $44,167 | $34,54913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 127 rheumatology providers in Tennessee.
Other rheumatology in Nashville
- Erin WilfongNashville$388K
- Robert CollinsNashville$383K
- Jason SpringerNashville$363K
- Narender AnnapureddyNashville$123K
- Leslie CroffordNashville$122K
- Robert LagroneNashville$113K
- Chad BoomershineNashville$105K
- Kevin ByramNashville$98K
- Christian RheaNashville$81K
- Tyler ReeseNashville$80K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.